|Day Low/High||47.48 / 49.09|
|52 Wk Low/High||29.50 / 67.10|
Bevyxxa Available to Patients in January 2018
The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).
Portola and WTD Aim to Make VTE Protocol and Prevention a Priority Patient Safety Issue in Hospitals Across the United States
Jim Cramer is bullish on Southwest, Delta, General Electric, and Portola Pharmaceuticals.
From Apple's orders and funds liquidating winners to the slow-growing cloud narrative, Jim Cramer explains why he thinks this is selloff is really an opportunity.
The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.
Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Portola Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Portola Pharmaceuticals, Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.